GB0328060D0 - Botulinum toxin treatment - Google Patents

Botulinum toxin treatment

Info

Publication number
GB0328060D0
GB0328060D0 GBGB0328060.9A GB0328060A GB0328060D0 GB 0328060 D0 GB0328060 D0 GB 0328060D0 GB 0328060 A GB0328060 A GB 0328060A GB 0328060 D0 GB0328060 D0 GB 0328060D0
Authority
GB
United Kingdom
Prior art keywords
bladder
unstable
sphincter
botulinum toxin
detrusor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0328060.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29764527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0328060(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to GBGB0328060.9A priority Critical patent/GB0328060D0/en
Publication of GB0328060D0 publication Critical patent/GB0328060D0/en
Priority to PL04798493T priority patent/PL1691828T3/pl
Priority to US10/581,671 priority patent/US20070275110A1/en
Priority to DK04798493.5T priority patent/DK1691828T3/da
Priority to JP2006541996A priority patent/JP5107578B2/ja
Priority to EP04798493A priority patent/EP1691828B1/en
Priority to ES04798493T priority patent/ES2347151T3/es
Priority to PCT/GB2004/004770 priority patent/WO2005053733A1/en
Priority to RU2006123561/15A priority patent/RU2350348C2/ru
Priority to CA2547618A priority patent/CA2547618C/en
Priority to PT04798493T priority patent/PT1691828E/pt
Priority to AT04798493T priority patent/ATE475429T1/de
Priority to DE602004028403T priority patent/DE602004028403D1/de
Priority to US12/155,104 priority patent/US8277822B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
GBGB0328060.9A 2003-12-04 2003-12-04 Botulinum toxin treatment Ceased GB0328060D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB0328060.9A GB0328060D0 (en) 2003-12-04 2003-12-04 Botulinum toxin treatment
AT04798493T ATE475429T1 (de) 2003-12-04 2004-11-12 Behandlung der spastischen blase mit botulinustoxin
DE602004028403T DE602004028403D1 (de) 2003-12-04 2004-11-12 Behandlung der spastischen blase mit botulinustoxin
EP04798493A EP1691828B1 (en) 2003-12-04 2004-11-12 Botulinum toxin treatment of spastic bladder
RU2006123561/15A RU2350348C2 (ru) 2003-12-04 2004-11-12 Лечение с применением ботулинического токсина
DK04798493.5T DK1691828T3 (da) 2003-12-04 2004-11-12 Behandling af spastisk blære med botulinustoksin
JP2006541996A JP5107578B2 (ja) 2003-12-04 2004-11-12 ボツリヌス毒素治療
PL04798493T PL1691828T3 (pl) 2003-12-04 2004-11-12 Leczenie toksyną botulinową spastycznego pęcherza
ES04798493T ES2347151T3 (es) 2003-12-04 2004-11-12 Tratamiento con toxina botulina de la vejiga espastica.
PCT/GB2004/004770 WO2005053733A1 (en) 2003-12-04 2004-11-12 Botulinum toxin treatment of spastic bladder
US10/581,671 US20070275110A1 (en) 2003-12-04 2004-11-12 Botulinum Toxin Treatment Of Spastic Bladder
CA2547618A CA2547618C (en) 2003-12-04 2004-11-12 Botulinum toxin treatment
PT04798493T PT1691828E (pt) 2003-12-04 2004-11-12 Tratamento de bexiga espástica através da toxina de botulinum
US12/155,104 US8277822B2 (en) 2003-12-04 2008-05-29 Botulinum toxin treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0328060.9A GB0328060D0 (en) 2003-12-04 2003-12-04 Botulinum toxin treatment

Publications (1)

Publication Number Publication Date
GB0328060D0 true GB0328060D0 (en) 2004-01-07

Family

ID=29764527

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0328060.9A Ceased GB0328060D0 (en) 2003-12-04 2003-12-04 Botulinum toxin treatment

Country Status (13)

Country Link
US (2) US20070275110A1 (https=)
EP (1) EP1691828B1 (https=)
JP (1) JP5107578B2 (https=)
AT (1) ATE475429T1 (https=)
CA (1) CA2547618C (https=)
DE (1) DE602004028403D1 (https=)
DK (1) DK1691828T3 (https=)
ES (1) ES2347151T3 (https=)
GB (1) GB0328060D0 (https=)
PL (1) PL1691828T3 (https=)
PT (1) PT1691828E (https=)
RU (1) RU2350348C2 (https=)
WO (1) WO2005053733A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
ES2509872T3 (es) 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
US20090304747A1 (en) * 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
CA2678038C (en) 2007-02-15 2016-10-11 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
MX2010004502A (es) 2007-10-23 2010-06-17 Allergan Inc Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas.
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
WO2011089604A2 (en) 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
RU2635466C2 (ru) * 2012-04-08 2017-11-13 Теракоат Лтд Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия
JP2017532301A (ja) * 2014-09-24 2017-11-02 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法
RU2605624C1 (ru) * 2015-11-23 2016-12-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) Способ лечения детрузорной гиперактивности
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
CA3201129A1 (en) 2020-12-11 2022-06-16 Yulia HIONIDI Material and method for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236956A (en) * 1988-11-04 1993-08-17 Kabi Pharmacia Aktiebolag Compounds for the treatment of urinary incontinence
SE8804003D0 (sv) * 1988-11-04 1988-11-04 Pharmacia Ab Compounds for the treatment of urinary incontinence
JPH0564661A (ja) * 1991-09-09 1993-03-19 Olympus Optical Co Ltd 体腔内挿入具
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5749845A (en) 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
KR100544060B1 (ko) * 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6630570B1 (en) * 1999-04-09 2003-10-07 Insitut für Diagnostikforschung GmbH Short-chain peptide-dye conjugates as contrast media for optical diagnosis
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6638246B1 (en) * 2000-11-28 2003-10-28 Scimed Life Systems, Inc. Medical device for delivery of a biologically active material to a lumen
US20020099356A1 (en) * 2001-01-19 2002-07-25 Unger Evan C. Transmembrane transport apparatus and method
DK1411978T3 (da) * 2001-07-27 2009-01-05 Univ Louisiana State Botulinum-toksin ved behandlingen eller forebyggelsen af acne
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US20040067235A1 (en) * 2002-07-29 2004-04-08 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders

Also Published As

Publication number Publication date
EP1691828B1 (en) 2010-07-28
JP2007513127A (ja) 2007-05-24
WO2005053733A1 (en) 2005-06-16
US20070275110A1 (en) 2007-11-29
RU2350348C2 (ru) 2009-03-27
CA2547618C (en) 2014-05-27
DE602004028403D1 (de) 2010-09-09
PL1691828T3 (pl) 2011-01-31
JP5107578B2 (ja) 2012-12-26
DK1691828T3 (da) 2010-11-01
EP1691828A1 (en) 2006-08-23
ATE475429T1 (de) 2010-08-15
ES2347151T3 (es) 2010-10-26
RU2006123561A (ru) 2008-01-10
US20090028907A1 (en) 2009-01-29
CA2547618A1 (en) 2005-06-16
PT1691828E (pt) 2010-10-04
US8277822B2 (en) 2012-10-02

Similar Documents

Publication Publication Date Title
GB0328060D0 (en) Botulinum toxin treatment
Smith et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra
CA2570406A1 (en) Use of botulinum toxin for treating pelvic pain
Raz et al. External sphincter spasticity syndrome in female patients
Yang et al. Endogenous Klebsiella endophthalmitis associated with pyogenic liver abscess
Moulin Pain in central and peripheral demyelinating disorders: Multiple sclerosis and Guillain-Barre syndrome
US8871763B2 (en) Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
JP2007513127A5 (https=)
Vera et al. MK-801, a non-competitive NMDA receptor antagonist, produces facilitation of the micturition reflex in awake, freely-moving rats
Schapiro The symptomatic management of multiple sclerosis
Rösche Treatment of spasticity
Pereira et al. Primary Nocardia brain abscesses and role of intraventricular antibiotic therapy
US11766460B2 (en) Pharmaceutical composition comprising amniotic fluid stem cell spheroid and the use thereof in treatment of urinary incontinence
Glazer et al. Clinical management of vulvodynia
Kroll The current role of Botox in a pediatric neurogenic bladder condition
RU2721300C2 (ru) Способ лечения нейрогенной дисфункции мочевого пузыря, проявляющейся функциональной инфравезикальной обструкцией у женщин
Chao et al. Duloxetine treatment of long-term ketamine abuse-related lower urinary tract symptoms: a case report
Kuo EFFECTIVENESS OF PERIURETHRAL BOTULINUM TOXIN INJECTION IN THE TREATMENT OF VOIDING DYSFUNCTION DUE TO DETRUSOR UNDERACTIVITY AND NON-RELAXING URETHRAL SPHINCTER
Fowler et al. Bladder dysfunction in multiple sclerosis
Mediratta Urinary Problems in Women: Hush No More
Dzigowski et al. Efficacy and safety of botulinum toxin non-neurogenic administration, a single center, single surgeon 7 years experience Article published in Urologia Polska 2008/61/Supl. 1.
Hatch Intraprostatic injection of penicillin
Ke et al. Clinical Application of Botulinum Toxin A in Lower Urinary Tract Dysfunction
UA72418A (en) Method for treating hyperactivity of urinary bladder
CN114042076A (zh) 一种肛门术后镇痛技术

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)